title: Strong human immunodeficiency virus (HIV)-specific CD4+ T cell responses in a cohort of chronically infected patients are associated with interruptions in anti-HIV chemotherapy.
abstract: Virus-specific CD4+ T-helper cell function is important in controlling human immunodeficiency virus (HIV) infection but is impaired in patients with progressive HIV disease. It has been reported that after highly active antiretroviral therapy (HAART), HIV-specific lymphoproliferative responses remain absent, whereas responses to non-HIV microbial antigens are restored. However, in analyzing immune responses in a cohort of chronically infected adults on HAART, we observed strong HIV-specific CD4+ T cell responses of Th-1 phenotype in 11 of 22 patients. The magnitude and frequency of HIV-specific lymphoproliferative responses was strongly associated with previous interruptions in HAART (P=.001). In contrast, the magnitude of CD8+ T cell responses to HIV Gag, Pol, Env, and Nef was similar in patients who had and those who had not interrupted HAART. We conclude that (1) a significant proportion of chronically HIV-infected patients on HAART can generate strong HIV-specific CD4+ and CD8+ T cell immunity and (2) transient interruptions in antiviral treatment may prime or boost HIV-specific CD4+ T-helper responses.
authors.affiliation: Laboratory of Cellular Physiology and Immunology, Rockefeller University, New York, NY 10021, USA. hasletp@rockvax.rockefeller.edu
authors.forename: P A
authors.initials: PA
authors.lastname: Haslett
authors.forename: D F
authors.initials: DF
authors.lastname: Nixon
authors.forename: Z
authors.initials: Z
authors.lastname: Shen
authors.forename: M
authors.initials: M
authors.lastname: Larsson
authors.forename: W I
authors.initials: WI
authors.lastname: Cox
authors.forename: R
authors.initials: R
authors.lastname: Manandhar
authors.forename: S M
authors.initials: SM
authors.lastname: Donahoe
authors.forename: G
authors.initials: G
authors.lastname: Kaplan
mesh_terms: D000328:Adult; D000368:Aged; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000914:Antibodies, Viral / Q000096:biosynthesis; D018791:CD4 Lymphocyte Count; D002469:Cell Separation; D015331:Cohort Studies; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005434:Flow Cytometry; D015683:Gene Products, gag / Q000096:biosynthesis; D006678:HIV / Q000502:physiology*; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology*; D006801:Humans; D007371:Interferon-gamma / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D006377:T-Lymphocytes, Helper-Inducer / Q000502:physiology*; D014779:Virus Replication
chemical_list: D019380:Anti-HIV Agents; D000914:Antibodies, Viral; D015683:Gene Products, gag; D007371:Interferon-gamma